![](/img/cover-not-exists.png)
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
Greene, Michelle K., Chen, Ting, Robinson, Eifion, Straubinger, Ninfa L., Minx, Charlene, Chan, Darren K. W., Wang, Jun, Burrows, James F., Van Schaeybroeck, Sandra, Baker, James R., Caddick, Stephen,Journal:
British Journal of Cancer
DOI:
10.1038/s41416-020-01046-6
Date:
September, 2020
File:
PDF, 1.75 MB
2020